首页|期刊导航|iLABMED|Integrating Biomarker-Based Fatty Liver Indices Into Multidisciplinary Treatment Pathways for Digestive Tumors

Integrating Biomarker-Based Fatty Liver Indices Into Multidisciplinary Treatment Pathways for Digestive TumorsOA

中文摘要

Dear Editor,We read the recent study by Ding et al.[1],which was published by iLABMED in 2025 with great interest in which the laboratory-based fatty liver index(FLI-L)and the physical examination-combined laboratory-based fatty liver index(FLI-PL)were developed and validated.

Xudong Song;Jingjing Dai;Guoquan Tao

Department of Gastrointestinal Surgery,The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University,Huai’an,ChinaDepartment of Medical Laboratory,The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University,Huai’an,ChinaDepartment of Gastrointestinal Surgery,The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University,Huai’an,China

医药卫生

digestive tumorfatty liver indexmetabolic-associated fatty liver diseasemultidisciplinary treatmentperioperative management

《iLABMED》 2026 (2)

P.130-131,2

supported by the National Natural Science Foundation of China(Grant 81773538)the Special Fund for the Construction of Key Medical Discipline Laboratories in Jiangsu Province(Grant JSDW202233)the Jiangsu Province’s Sixth“333 Project”Talent Support Special Fund(Grant S333YQ002).

10.1002/ila2.70056

评论